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Abstract  23	
Skeletal muscles have a fundamental role in locomotion and whole body metabolism, 24	
with muscle mass and quality being linked to improved health and even lifespan. 25	
Optimising nutrition in combination with exercise is considered an established, 26	
effective ergogenic practice for athletic performance. Importantly, exercise and 27	
nutritional approaches also remain arguably the most effective countermeasure for 28	
muscle dysfunction associated with ageing and numerous clinical conditions e.g. 29	
cancer cachexia, COPD and organ failure, via engendering favourable adaptations 30	
such as increased muscle mass and oxidative capacity. Therefore, it is important to 31	
consider the effects of established and novel effectors of muscle mass, function and 32	
metabolism in relation to nutrition and exercise. To address this gap, in this review we 33	
detail existing evidence surrounding the efficacy of a non-exhaustive list of 34	
macronutrient, micronutrient and “nutraceutical” compounds alone and in 35	
combination with exercise in relation to skeletal muscle mass, (protein and fuel) 36	
metabolism and exercise performance (i.e. strength and endurance capacity). It is long 37	
established that macronutrients have specific roles and impacts upon protein 38	
metabolism and exercise performance i.e. protein positively influences muscle muscle 39	
mass and protein metabolism, whilst carbohydrate and fat intakes can influence fuel 40	
metabolism and exercise performance. Regarding novel nutraceuticals, we show the 41	
following ones in particular may have effects in relation to: 1) muscle mass/protein 42	
metabolism: leucine, hydroxyl β-methylbutyrate, creatine, vitamin-D, ursolic acid and 43	
phosphatidic acid, and 2) exercise performance: (i.e. strength or endurance capacity); 44	
hydroxyl β-methylbutyrate, carnitine, creatine, nitrates and β-alanine.  45	
Key words: nutrients, metabolism, exercise, skeletal muscle, nutraceuticals 46	
 47	
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Introduction 48	
Skeletal muscle represents the largest organ in the body, comprising ~40% of whole 49	
body mass (123). The functions of skeletal muscle extend beyond the widely 50	
recognized role of locomotion, serving as the bodies’ largest tissue for glucose storage 51	
and utilization (101, 121) and a primary site of lipid metabolism (104). Muscle also 52	
stores ~40% of total body amino acids (AA), that can act as a source of fuel and an 53	
AA substrate for other tissues in times of illness or fasting via release of glucogenic, 54	
ketogenic AA (264). Changes in muscle mass are regulated by dynamic turnover of 55	
the muscle protein pool (~1-1.5 %/day) with skeletal muscle mass remaining constant 56	
when muscle protein synthesis (MPS) and muscle protein breakdown (MPB) are in 57	
balance (8). During situations of muscle growth, (e.g. resistance exercise training 58	
(RET) combined with AA substrate), net MPS exceeds MPB (8). Conversely, net 59	
MPB is greater than MPS in conditions of muscle loss (e.g. bed rest, cachexia and 60	
sarcopenia (75)); in humans such wasting conditions are typically predominantly due 61	
to reduced MPS under fasted and/or fed conditions (191)). In addition to the 62	
regulation of muscle and function being clinically relevant, optimal strategies to 63	
promote growth, maintenance of muscle mass and exercise performance (i.e. strength 64	
and endurance capacity) are of great interest to performance scientists. Therefore, a 65	
major area of interest surrounds the role of macronutrients, micronutrients and 66	
nutraceuticals that influence muscle metabolism and function.  67	
 68	
The consumption of nutritional supplements with “ergogenic” claims occurs in many 69	
populations including athletes (186), the elderly (24), chronic disease sufferers (78) 70	
and sedentary (201) adults, often without sound empirical evidence. As such there is a 71	
need to review the continually growing area of nutrients/ nutraceuticals and associated 72	
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mechanisms on aspects of skeletal muscle health, in order to formulate evidenced-73	
based recommendations. Indeed, previous reviews have summarized the effects of 74	
multiple nutrient/nutraceutical compounds on aspects of skeletal muscle metabolism 75	
and exercise performance (53, 171). Often such reviews target a specific population 76	
(e.g. athletes), endpoint (i.e. aerobic performance), or dosing regime (e.g. timing and 77	
amount). As such, the present review adopts a more wide-ranging scope, including 78	
data irrespective of age, training status, or other independent variables, in order to 79	
highlight universal skeletal muscle effects of each nutritional compound.  80	
 81	
Herein, we detail existing evidence for a non-exhaustive list of established and 82	
emerging nutrients in relation to some or all of the following endpoints: 1) muscle 83	
mass; 2) metabolism (protein and fuel) and, 3) exercise performance (i.e. strength and 84	
endurance capacity). Since nutrition and exercise are the two key modifiable lifestyle 85	
factors for maintaining muscle health, this review will critique available literature 86	
examining the muscular responses to nutrient supplementation alone, nutrient 87	
supplementation plus acute exercise and chronic nutrient supplementation combined 88	
with chronic exercise training (i.e. more than one bout of exercise). We shall include 89	
responses to both resistance exercise (RE)/RET and endurance exercise/endurance 90	
exercise training (EE/EET) since exercise mode may differentially influence muscular 91	
responses to nutrition. Lastly, due to the emerging nature of some nutrients, where 92	
mechanisms have not been well defined in humans, data from other models (e.g. 93	
cell/rodents) have been drawn upon where necessary. Therefore, this review should be 94	
of interest to scientists, clinicians, and athletes aiming to optimize muscle mass and 95	
function in clinical and athletic populations. Out of the scope of this review are a 96	
selection of established nutrients with purported effects on muscle (e.g. caffeine and 97	
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green tea) due to the large volume of existing review literature available. 98	
Furthermore, some emerging nutrients (e.g. tomatidine and minerals) have been 99	
omitted from this review due to the paucity of existing literature. We therefore direct 100	
readers to the following publications for further reading regarding nutrients not 101	
discussed herein (53), in particular; caffeine (96), green tea (114), tomatidine (69) and 102	
minerals (209). Since we have not performed a systematic analysis, we apologize to 103	
those whose work we have not alluded to.  104	
 105	
Definitions of macro/micronutrients and “nutraceuticals” 106	
From the outset it is important that we define what is meant when we refer to 107	
macronutrients, micronutrients and nutraceuticals, since the classification can be 108	
misinterpreted due to obscure classification boundaries. Proteins, fats and 109	
carbohydrate (CHO) are required by the body in large amounts (i.e. g/kg/day), and are 110	
therefore termed macronutrients (139). Micronutrients are defined as vitamins and 111	
trace elements (minerals) (212, 213) essential to our diet, albeit in small amounts (i.e. 112	
mg/kg/day), to maintain normal physiological and metabolic function. Nutraceuticals 113	
is an emerging term within the scientific literature, which has not been well defined. 114	
A recent review defined a nutraceutical as a nutrient compound “with added extra 115	
health benefits” (i.e. in addition to the basic nutritional value contained in foods) 116	
(210). For the purpose of this review we define a nutraceutical as: “a compound that 117	
alone or in tandem with exercise, impacts major physiological end-point(s)” e.g. 118	
effectors of whole body metabolism, skeletal muscle mass and/or whole body/muscle 119	
function. 120	
 121	
Established macronutrients and exercise 122	
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Providing a mixed macronutrient feed containing protein, CHO and fat stimulates 123	
MPS (200). The absolute stimulation of MPS is highly dependent on the AA content, 124	
with the provision of AA alone being sufficient to maximally stimulate MPS (15); this 125	
effect is entirely attributable to the essential AA (EAA) (218). Of the EAA, the 126	
branched chain AA (BCAA) provide the most potent anabolic stimulation (9), 127	
particularly leucine (9, 256). This stimulation of MPS by AA is highly dose 128	
dependent and saturable, with maximal stimulation provided by between 20-40g of 129	
high quality protein (166, 167, 230, 263)) or 10-20g of EAA (58). Furthermore, this 130	
MPS stimulation is finite, where following an initial lag-period of ~30 minutes during 131	
I.V infusion (or ~45-60 minutes following oral ingestion – to allow for the digestion, 132	
absorption and transport of AA into the systemic circulation), the rate of MPS is 133	
increased ~2-3-fold reaching a maximum by 1.5-3h. Subsequently rates of MPS 134	
return to baseline (~2-3h post ingestion) despite continued plasma and muscle AA 135	
availability and elevated anabolic signaling (7). Thereafter, muscle remains refractory 136	
to further stimulation for an as yet undefined period; a phenomenon coined “muscle 137	
full” (7). This ~2-3h period of MPS stimulation can be extended depending on the 138	
type and dose of AA and macronutrient co-ingestion in combination with RE (51). 139	
The timing of protein ingestion in close proximity to the performance of acute RE, 140	
which when performed alone stimulates MPS for ~48h (190), is thought to be 141	
important. This is because there is an enhanced sensitivity of the muscle to the 142	
anabolic properties of AA for at least 24h post-exercise (36), synergistically 143	
impacting MPS. However, protein ingestion before (236), during (14), 1h or 3h (199) 144	
after RE have all elicited similar post-exercise increases in MPS.  145	
 146	
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The mechanisms underlying the anabolic effects to nutrition involve both the 147	
stimulation of MPS (200) and suppression of MPB (255); however, it is generally 148	
accepted that increases in MPS is the primary driver (8). Following transportation into 149	
the muscle cell, leucine in particular stimulates mammalian target of rapamycin 150	
complex-1 (mTORC1) (9), which is considered a key regulator of cell growth. 151	
mTORC1 activation leads to the phosphorylation of the downstream translation 152	
initiation factors 4E-binding protein (4EBP1) and 70-kDa ribosomal protein S6 kinase 153	
1 (p70S6K1) (see Figure 1), stimulating the binding of eukaryotic initiation factor 4A 154	
(eIF4A) and 4E (eIF4E) to 4G (eIF4G) to form the 4F (eIF4F) complex (135). The 155	
eIF4F complex promotes the assembly of the 48S preinitiation complex, via 156	
mediating the binding of mRNA to the 43S preinitiation complex, thereby promoting 157	
MPS (135). Currently the AA sensor coupling intracellular AA signaling to mTORC1 158	
remains to be fully defined, although Rag GTPases (207), leucyl-tRNA synthetase 159	
(105) and sestrin2 (265) are all proposed candidates. This has led to intense interest 160	
into the development of novel leucine enriched supplementation regimes to aid 161	
maintenance of muscle mass (44, 249). Unlike dietary protein, neither fats nor CHO 162	
lead to a direct stimulation of MPS (91, 95, 138); nonetheless, they can influence the 163	
bioavailability of AA when provided as part of a mixed meal - slowing plasma AA 164	
appearance and increasing AA retention (84) without blunting muscle anabolism (95). 165	
Finally, CHO (as well as AA (172, 173)) are insulin secretagogues, positively 166	
impacting net muscle anabolism via inhibition of MPB (255) (rather than stimulation 167	
of MPS (102, 255)).  168	
 169	
Exercise combined with feeding extends the stimulation of MPS (59) thereby 170	
delaying the “muscle full” set-point (8). It is the cumulative stimulation of muscle 171	
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protein turnover with repeated bouts of exercise and feeding that drives exercise-172	
induced skeletal muscle remodeling and hypertrophy (29). The impact of 173	
macronutrient supplements on exercise adaptation is multifarious. It is established that 174	
CHO intake helps to spare muscle and liver glycogen stores, whilst also leading to a 175	
more rapid recovery of these stores post exercise (47, 162). The benefits of chronic 176	
protein supplementation alongside exercise are more inconsistent, with a number of 177	
studies showing positive (120, 134, 259) or negligible findings (149, 198, 242). 178	
However, a recent meta-analysis suggested that overall, protein supplementation does 179	
lead to an augmentation of muscle mass and strength gains during chronic RET (49). 180	
To conclude, it is now well established that macronutrients play key roles in 181	
promoting muscle mass maintenance/ growth and functional adaptations. Future work 182	
should focus on identifying the underlying cellular mechanisms and associated 183	
refractory period of “muscle-full”.  184	
 185	
Emerging nutraceuticals and exercise 186	
 187	
Leucine metabolites  188	
Leucine, as a BCAA can be metabolized within muscle, engendering the possibility 189	
that its metabolites harbor anabolic effects. For instance, the keto-acid derivative of 190	
leucine metabolism, alpha-ketoisocaproate (KIC), was shown to stimulate MPS when 191	
provided by infusion; however this effect could simply be due to KIC being reversibly 192	
transaminated to leucine (74). There is however, good evidence of anabolic activities 193	
of the more distal leucine metabolite, β-hydroxy-β-methylbutyrate (HMB) produced 194	
via cytosolic KIC dioxygenase (174). Ingestion of ~3g HMB in humans elicited 195	
comparable increases in MPS to 3g of leucine, whilst also suppressing MPB 196	
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independently of insulin (256). Similarly to leucine, the stimulation of MPS by HMB 197	
is attributable to enhanced mTORC1 signaling (256). In order to understand the 198	
insulin-independent suppression of MPB associated with HMB, numerous molecular 199	
targets associated with different proteolytic pathways (beclin 1, calpain 1, MuRF1, 200	
Mafbx and cathepsin L) have been investigated, although no detectable changes in the 201	
protein abundance or post-translational modifications were observed (256). Although 202	
it has been previously shown that there is a disparity between protein breakdown and 203	
the abundance in proteolytic proteins (102). It should be noted that only small 204	
amounts of HMB (~5%) are generated from normal leucine metabolism (137) 205	
meaning that in order to obtain 3g of HMB (a commonly supplemented amount) one 206	
would have to consume 60g leucine (260). Thus, when supplementing with 207	
physiological doses of leucine it is unlikely that HMB is the main anabolic 208	
constituent, hence the practical use of HMB as a stand alone nutritional supplement.  209	
 210	
Indeed, longer term studies have found that HMB preserved muscle mass during 211	
periods of disuse (65), while year long supplementation of HMB (plus arginine and 212	
lysine) in the elderly led to improved preservation of lean body mass, possibly due to 213	
an augmentation in muscle protein turnover (10). Although, since HMB was 214	
administered as part of a nutritional cocktail it is impossible to delineate whether 215	
HMB was solely responsible for the effects on lean body mass. However, recent 216	
meta-analysis of 287 elderly participants (147 HMB-supplemented and 140 controls) 217	
found HMB supplementation led to greater gains in muscle mass compared to 218	
controls, indicating HMB is an effective ergogenic aid, at least in the elderly 219	
population, for preventing the loss of lean body mass (268). These anabolic properties 220	
of HMB have also been suggested to facilitate favorable RET adaptations. For 221	
	 10	
example, supplementation of HMB (3g/day) with RET for between 4 and 7 weeks led 222	
to heightened increases in muscle strength (181), lean body mass (261) and fat free 223	
mass (174) compared with RET alone. However, not all studies have reported positive 224	
effects; for instance RET for 1 month combined with between 3 to 6g/day of HMB 225	
did not change parameters of body composition in RE trained males (140). In this 226	
latter case, HMB was provided in its calcium form (CaHMB) (140), which compared 227	
to the free acid form (FA-HMB), may have lower bioavailability and therefore might 228	
not enhance anabolism to the same extent (82) (though this premise remains to be 229	
tested). 230	
 231	
Another ergogenic effect of HMB is the purported ability to attenuate exercise-232	
induced muscle damage (EIMD). For example, oral HMB supplementation (3g/day 233	
for 6 weeks) in EE athletes attenuated the increase in creatine phosphokinase and 234	
lactate dehydrogenase (plasma markers of EIMD) after a 20 km time trial run 235	
compared to placebo (136). This protective effect of HMB may be due to HMB being 236	
a precursor of de novo cholesterol synthesis (175), which is critical for cell membrane 237	
(sarcolemmal) maintenance. Thus, HMB may maintain muscle membrane integrity 238	
during bouts of damaging exercise. 239	
 240	
Furthermore, HMB has been shown to be efficacious for improving EE performance. 241	
For example, Vukovich et al. (2001) reported that HMB in combination with EE 242	
prolonged the time to reach the onset of blood lactate accumulation and VO2PEAK, 243	
although via an unknown mechanism (246). Others have investigated markers of 244	
endurance performance following high intensity interval training (HIIT) with or 245	
without HMB supplementation. To exemplify, following 5 weeks of HIIT-based 246	
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running in combination with 3g/d ca-HMB, VO2MAX improved more compared to 247	
placebo (144). The authors speculated that the performance benefits were attributable 248	
to the preservation of the cell-membrane, however was membrane stability was not 249	
measured in the study and thus no mechanistic conclusions can be drawn. 250	
Furthermore, HMB in untrained participants potentiated the effects of HIIT on 251	
physical working capacity at the onset of neuromuscular fatigue, compared to HIIT 252	
training alone (163).  253	
 254	
In summary, the literature supports a role for HMB supplementation in promoting: 1) 255	
muscle mass, demonstrated by the preservation or increase in muscle mass when 256	
combined with RET, 2) muscle metabolism, since HMB stimulates MPS and inhibits 257	
MPB, and 3) aerobic and strength performance. However, data reporting negligible 258	
effects of HMB does exist (140, 214); prior exercise training history and/or being 259	
accustomed to an exercise stimulus may determine the effectiveness of the 260	
intervention. This is supported by evidence that HMB supplementation combined 261	
with RET in trained individuals had no effect on muscle strength or lean body mass 262	
versus placebo (214). Further research is warranted which rigorously investigates: 1) 263	
the mechanisms regulating the insulin-independent suppression of MPB associated 264	
with HMB supplementation, 2) the effects of novel and accustomed exercise in 265	
combination with HMB on endurance performance, and 3) the effects of EET and 266	
HMB on muscle mass.  267	
 268	
Creatine 269	
Creatine (Cr) is an endogenously formed metabolite synthesised from arginine, 270	
glycine and methionine (20). Found almost exclusively in skeletal muscle, Cr levels 271	
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can be increased via endogenous synthesis in the liver and pancreas or exogenously 272	
from foodstuff, particularly meat and fish (43, 99). Following oral consumption of Cr, 273	
Cr is absorbed into the systemic circulation and is taken up by skeletal muscle via the 274	
sarcolemal Na+/Cl--dependent transporter, soluble carrier family 6 member 8 275	
(SLC6A8) (126). Intramuscular Cr can then be phosphorylated to phosphocreatine in 276	
a reversible reaction facilitated by the enzyme, creatine kinase. During high energy 277	
demands, the phosphate of phosphocreatine plus free ADP is used for ATP synthesis 278	
(126). Another fate of intramuscular Cr is the conversion to the end-product 279	
creatinine, which due to its muscle exclusivity correlates with muscle mass (110). 280	
Creatinine diffuses out of the muscle cell and is removed from the body via urine 281	
(126). Oral Cr administration (20-30g/day for 2 or more days) increases total muscle 282	
Cr stores by >20%, of which 20-30% is stored in the form of phosphocreatine (PCr) 283	
(107). The greatest Cr loading effects are seen in those with the lowest basal Cr pool 284	
levels i.e. vegetarians (99), thus basal muscle Cr levels are an important determinant 285	
of Cr uptake (43, 107). The ergogenic effects of Cr are facilitated by elevated resting 286	
PCr, which sustains PCr-mediated ATP resynthesis during intense anaerobic exercise 287	
(42) primarily in fatigue susceptible type II fibers (43), thus improving acute high 288	
intensity performance. Increased basal muscle PCr levels also expedite the 289	
replenishment of PCr stores during recovery from intense exercise, leading to 290	
improved performance over repeated bouts of sprint exercise (43, 99). For example, 291	
20g/day of Cr for 5 days led to sustained isokinetic torque compared to placebo 292	
during repeated bouts of maximal voluntary contractions (100). Similar results have 293	
been obtained when employing different exercise modes such as cycling (18, 70). In 294	
contrast, some studies have shown no effect of Cr supplementation on exercise 295	
performance (55, 170, 219, 234). For example, despite increased total muscle Cr 296	
	 13	
following 5 days 30g Cr (and 30g dextrose) supplementation, there were no 297	
improvements in sprint exercise performance (219). A lack of ergogenic effect may 298	
be attributable to the small total muscle Cr levels of ~12mmol/kg/dry weight (219), 299	
where previous reports show total Cr of >20 mmol/kg dry mass results in ergogenic 300	
benefit (42). Factors affecting the extent to which muscle Cr stores increase are not 301	
well known, although pre-existing muscle Cr, exercise (107) and CHO ingestion (98) 302	
may be potential factors. Also in regards to performance, Cr supplementation 303	
improves the rate of functional recovery following exercise (54), which might be 304	
mediated by Cr promoting gene expression thereby aiding MPS during the recovery 305	
periods (54, 258), ultimately increasing the deposition of newer functional proteins 306	
for improved functional recovery. Indeed, Cr supplementation will also increase 307	
muscle PCr, which might increase local rephosphorylation from ADP to ATP (54), 308	
thus providing more energy for contraction. As such, performance during successive 309	
bouts is maximized (i.e. can work at higher training loads) which, in-turn, may 310	
contribute to the gains in strength observed when combined with RET (31, 63, 66).  311	
 312	
In addition to energetic impacts, evidence supports a role for chronic Cr 313	
supplementation, typically provided as a loading dose (i.e. ~5 days of 20/30g) 314	
followed by maintenance doses (~ 5g) (32), for increasing muscle mass (25, 31, 245). 315	
For example 12 weeks RET plus Cr (25g/day for the first week, followed by a 316	
maintenance dose of 5g/day for the rest of the training duration) resulted in 317	
significantly greater fat free mass, strength and fibre cross sectional area gains 318	
compared to placebo (245). Similarly, 14 weeks of whole body RET (3 x/week) 319	
combined with Cr (5g/day plus 2g dextrose) led to significantly greater gains in fat 320	
free mass (31). Furthermore, a recent meta-analysis concluded that Cr 321	
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supplementation combined with RET elicited further increases in fat free mass 322	
compared to RET alone (albeit in older adults) (66). This meta-analysis reported a 323	
weighted mean difference (WMD) of 1.33kg for RET combined with Cr (66), 324	
compared to 0.69kg for RET with protein (49) demonstrating the potent ergogenic 325	
effect of Cr on fat free mass. The mechanisms regulating the effects of Cr on muscle 326	
mass remain to be fully elucidated; although it is known that acute provision of Cr 327	
does not directly stimulate MPS either with (152) or without RE (153). However, Cr 328	
did augment the satellite cell (SC) response following RE (178), which may 329	
contribute to hypertrophic gains since increased SC content is observed following 330	
chronic RET (241). Although the contribution of SC to hypertrophy is still debated 331	
(158), theoretically the nucleus content in hypertrophying muscle fibres becomes 332	
diluted such that additional nuclei are required for continued growth. As such, SC 333	
fuse and donate nuclei to the pre-existing muscle fibres, thereby increasing the 334	
transcriptional capacity of the muscle cell and thus the potential for growth (30). 335	
Additionally, augmented PCr availability and ATP resynthesis during intense exercise 336	
likely permits greater work output. Greater work may be a factor which stimulates 337	
greater muscle gene expression thereby promoting muscle mass accretion observed 338	
with Cr supplementation (32, 204, 257). It is possible that changes in fat free mass 339	
may be in part attributable to the osmotic potential of elevated intracellular Cr leading 340	
to myocellular water retention (204, 273). This potential increase in cell volume from 341	
Cr-induced fluid retention may then act as an anabolic signal, activating intracellular 342	
signalling cascades that maintain cellular function (204). For example, the attachment 343	
complex protein focal adhesion kinase (FAK), which is critical for osmosensing and 344	
hypertrophic signalling (56), is up-regulated following Cr supplementation (204). 345	
 346	
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To summarize, Cr supplementation is capable of increasing total muscle Cr stores 347	
which improves performance via maintaining PCr mediated ATP re-synthesis, 348	
although not all studies have shown improved exercise performance. Beyond 349	
performance, chronic Cr supplementation combined with RET is capable of 350	
stimulating muscle mass accretion. Although, acute affects of Cr supplementation on 351	
MPS are not shown, potentiating RET capacity and enhanced recovery likely mediate 352	
increased muscle mass. Further studies are needed to firmly establish factors which 353	
determine the variability of Cr storage in muscle, since this could have implications 354	
for optimizing the dosing regime of Cr. 355	
 356	
Carnitine  357	
Carnitine is synthesized endogenously from AA precursors and can also be obtained 358	
exogenously from the diet, particularly red meat, with the majority of whole body 359	
carnitine (95%) being stored in skeletal muscles (26). Carnitine has well documented 360	
roles in regulating the translocation of long-chain fatty acids into the mitochondrial 361	
matrix for subsequent β-oxidation (223). This process is regulated via the 362	
mitochondrial enzyme carnitine palmitoyltransferase 1 (CPT1) catalysing the 363	
esterification of carnitine with long-chain acyl-coA (223). The long chain 364	
acylcarnitine is transported across the mitochondrial membrane into the mitochondrial 365	
matrix, concurrently with the exchange of free carnitine from the mitochondrial 366	
matrix (94). Inside the mitochondrial matrix, acylcarnitine is transesterified to long 367	
chain acyl-CoA and free carnitine via carnitine palmitoyltransferase 2 (CPT2) (223). 368	
Subsequently, the long chain acyl-CoA is able to undergo β-oxidation. Readers are 369	
directed towards the review by Stephens et al., (223) for a more comprehensive 370	
overview regarding the role of carnitine in fatty acid translocation.  371	
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 372	
Therefore, increasing muscle carnitine content could hypothetically enhance fat 373	
oxidation whilst sparing glycogen, therein posing an attractive ergogenic strategy for 374	
delaying fatigue during prolonged aerobic exercise and aiding body weight control by 375	
promoting fat oxidation. However, a number of studies have failed to increase muscle 376	
carnitine via intravenous infusion despite increasing plasma carnitine availability 377	
(225). Similarly, oral consumption of carnitine acutely (220) and chronically (247) 378	
failed to increase muscle carnitine levels. It is likely the poor bioavailability of oral 379	
carnitine and rapid urinary clearance (106) explain, at least partly, why carnitine 380	
supplementation alone does not increase muscle carnitine stores (225). Consequently, 381	
several strategies have been tested to stimulate muscle carnitine accretion; concurrent 382	
hyperinsulinaemia and hypercarnitineaemia increased human muscle carnitine content 383	
by ~15% (225) and carnitine plus CHO supplementation promoted muscle carnitine 384	
accretion (211). Mechanisms by which insulin can facilitate increased muscle 385	
carnitine are purported to be due to insulin increasing Na+-dependent active transport 386	
of carnitine into the muscle via organic cation transporter (OCTN2) (225). Similarly, 387	
Na+-dependent uptake of AA (274) and Cr (97) by skeletal muscle is increased by 388	
insulin, thereby supporting the proposed mechanisms of carnitine uptake (225). 389	
However, CHO in addition to protein blunts the stimulation of muscle carnitine 390	
uptake (211). This was previously suggested to be related to AA inhibiting carnitine 391	
intestinal absorption (233), however, since the combination of CHO and protein led to 392	
greater plasma and urinary carnitine versus CHO alone, this suggests otherwise (211). 393	
The precise mechanisms underlying the blunting effect of protein on carnitine uptake 394	
into skeletal muscle remain to be fully identified.  395	
 396	
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By increasing muscle carnitine content, human fuel metabolism can be manipulated. 397	
For example, acute increases in resting skeletal muscle carnitine content led to an 398	
inhibited glycolytic flux (denoted by reduced lactate) and CHO oxidation 399	
(demonstrated via reduced pyruvate dehydrogenase complex activity) concurrent with 400	
increased muscle glycogen and long-chain acyl-CoA accumulation (224). These 401	
studies therefore support the notion that carnitine can enhance fat oxidation whilst 402	
sparing glycogen. A subsequent study by the same group found a 30% increase in 403	
muscle carnitine content following dietary carnitine (1.36g) and CHO (80g) twice a 404	
day for 6 months and a ~55% reduction in glycogen use during low intensity exercise 405	
(30 minutes cycling at 50% VO2max) compared to controls (250). Additionally, 406	
following 3 months supplementation, carnitine and CHO feeding prevented the 2kg 407	
increase in body mass, which was seen in the control group (250). The authors 408	
speculate that the lack of increase in body mass in the carnitine group may be due to 409	
carnitine-induced increases in long-chain fatty acid oxidation (250).  410	
 411	
Subsequent studies have supported the role of carnitine combined with CHO for the 412	
prevention of fat gain, which was associated with increased fat oxidation during low 413	
intensity exercise (227). Conversely, increased CHO but not fat oxidation during 414	
steady-state exercise has been reported following 2 weeks of carnitine 415	
supplementation (3g/day carnitine and tartrate combined with CHO meals) (1), and 1 416	
month of carnitine intake (3g/day carnitine and tartrate) had no effect on substrate 417	
oxidation during steady-state exercise (27). These findings conflict with those 418	
reported at rest and differ from hypotheses which suggest limited carnitine availability 419	
may limit fat oxidation during exercise (224). Interestingly, in the study by Broad and 420	
colleagues (27) there was no mention of daily carnitine supplementation being co-421	
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ingested with supplemental CHO, which is critical for increasing muscle carnitine 422	
stores (226). Therefore the protocol might have been suboptimal for increasing 423	
muscle carnitine stores, which was not measured within the study, and thus may 424	
explain the negligible effect of carnitine on substrate utilisation.  425	
 426	
Thus, insulin-stimulated carnitine uptake is capable of increasing muscle carnitine 427	
stores (when combined with CHO), which promotes fat oxidation, spares muscle 428	
glycogen and thereby improves endurance performance. Further work is required to 429	
fully elucidate the mechanisms regulating the blunting of carnitine uptake when 430	
combined with CHO and protein.  431	
 432	
n-3 polyunsaturated fatty acids  433	
n-3 polyunsaturated fatty acids (n-3 PUFA), contain a double bond at the third 434	
carbon atom from the end of the carbon chain. Abundantly found in walnuts and oily 435	
fish, there are 3-types of n-3 PUFA: 1) alpha-linoleic acid (ALA), 2) 436	
eicosapentaenoic acid (EPA), and 3) docosahexaenoic acid (DHA). n-3 PUFA serve 437	
well established roles as critical components of cell membranes and as substrates for 438	
lipid signaling (37). Early evidence demonstrated a role for n-3 PUFA in muscle 439	
anabolism when n-3 PUFA-enriched feed provided to growing steers increased the 440	
phosphorylation of anabolic signaling and the non-oxidative whole-body disposal of 441	
AA, representative of increased whole-body protein synthesis (85). Additionally, 442	
fish oil containing 18% EPA attenuated the loss of skeletal muscle following 30% 443	
burn in guinea pigs, which may be mediated by EPA reducing inflammatory related 444	
prostanoids (4). Hence there is interest for the application of n-3 PUFA as a 445	
nutritional supplement in humans. It has been suggested that fish oil 446	
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supplementation in humans may increase muscle n-3 PUFA content (160), have 447	
anti-inflammatory properties (128) via reduced leukotriene B4 formation (an inducer 448	
of inflammation) (79) and attenuate the loss of muscle mass in disease states, 449	
possibly via reductions in pro-inflammatory cytokines (203). Furthermore, n-3 450	
PUFA might potentiate anabolic responses to nutrition in skeletal muscle. In support 451	
of this, 8 weeks n-3 PUFA supplementation (1.86g EPA plus 1.5g DHA/day) was 452	
shown to augment hyperaminoacidaemia-hyperinsulinemia induced increases in 453	
mixed MPS compared to corn oil controls in young, middle aged and older adults 454	
(215, 216). Indeed, enhanced phosphorylation of mTORC1 and the downstream 455	
target p70S6K1 were observed in young, middle aged and older adults (215, 216). 456	
However, MPS increases were observed in the context of hyperaminoacidaemia and 457	
hyperinsulinemia, which may not be physiologically obtainable. Moreover, 458	
supplementation of n-3 PUFA for 3 (151) and 6 months (217) led to increases in 459	
muscle mass and function in older adults. A recent study in C2C12 skeletal muscle 460	
cells found a 25% increase in MPS following EPA that was not observed following 461	
DHA (131), suggesting that EPA may be the more anabolic constituent of n-3 462	
PUFAs. Interestingly, both EPA and DHA stimulated p70S6K1, thus EPA might 463	
stimulate MPS via a p70S6K1 independent mechanism (131).  464	
 465	
Despite being less well defined, these positive effects of n-3 PUFA on muscle 466	
appear to be recapitulated when combined with exercise (202). Supplementation 467	
during 3 months RET promoted increases in muscle strength in older women (202), 468	
suggesting that n-3 PUFA could have a positive role on muscle protein metabolism 469	
by enhancing the anabolic response to RE (90). Despite recent contrasting findings 470	
that chronic fish oil supplementation failed to increase muscle anabolism in younger 471	
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people under rested and exercise trained conditions (161), the lack of pre- and post-472	
intervention measurements confound interpretation of these results. Additionally, 473	
positive findings regarding the efficacy of n-3 PUFA supplementation have been 474	
largely observed in older adults. Because ageing associates with blunted anabolic 475	
responses to AA and exercise, the muscular benefits of n-3 PUFA may be more 476	
pronounced in those in which anabolic responses are already sub-optimal.  477	
 478	
Whilst the combination of EE and n-3 PUFA have not been investigated in the 479	
context of muscle mass and protein metabolism, there is sound evidence to suggest 480	
that n-3 PUFA supplementation may alter fuel metabolism by improving metabolic 481	
flexibility, i.e. the ability to switch between using fat or CHO as a fuel source. For 482	
example, 6g/day of fish oil for 3 weeks led to a 35% increase in fat oxidation 483	
following a glucose or fructose bolus (61). In the context of exercise, 3 weeks fish 484	
oil supplementation (6g/day) led to a non-significant trend for greater fat oxidation 485	
during an acute bout of cycling (90 minutes at 60% O2 output), a possible 486	
compensatory response for the lower CHO oxidation (62). Further studies have 487	
found significantly greater fat oxidation during EE in humans following 3 weeks 488	
fish oil supplementation (119). Although, each of these studies lacked 489	
comprehensive investigation into the mechanisms regulating changes in metabolic 490	
flexibility, n-3 PUFA have been shown to mediate the up-regulation of genes 491	
regulating mitochondrial biogenesis, such as peroxisome proliferator-activated 492	
receptor-alpha (PPARα) and -gamma (PPARγ) and the transcription factor nuclear 493	
respiratory factor 1 (NRF1) in mice (146), offering a potential explanation for these 494	
findings. Additionally, rats fed a low fat diet supplemented with DHA had higher 495	
oxygen consumption and apparent Km for ADP in permeabilised muscle fibres 496	
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compared to placebo, indicative of improved mitochondrial function (103). Thus, 497	
effects on mitochondrial biogenesis and function may underpin the synergistic 498	
effects of n-3 PUFA and EE-associated metabolic adaptation.  499	
 500	
Collectively, n-3 PUFA supplementation beneficially effects muscle protein 501	
metabolism, which may contribute to chronic gains in muscle mass, and also shows 502	
promise for impacting metabolic flexibility. Further human research is warranted 503	
which investigates the effects of EPA and DHA individually on aspects of skeletal 504	
muscle health to establish which is the main anabolic constituent.  505	
 506	
Nitrates 507	
Nutrients that contain dietary inorganic nitrates (e.g. beetroot and lettuce) or related 508	
precursors (e.g. arginine) can increase nitric oxide (NO) availability, which is 509	
capable of modulating muscle-related processes including contraction, glucose 510	
homeostasis, blood flow (127) and satellite cell activation (5, 35). Following oral 511	
ingestion of dietary nitrate-rich foods, nitrate (NO3-) is reduced to nitrite (NO2-) via 512	
nitrate reductases within the mouth (68). Subsequently, NO2- is converted into NO 513	
and additional reactive nitrogen species in the acidic environment of the stomach 514	
(2). Oral NO3- increases plasma NO3- and NO2- levels, indicating nitrates are 515	
bioavailable.  With regards to muscle protein turnover, these compounds are thought 516	
to promote anabolism via improving blood flow (through increased NO production), 517	
thus enhancing nutrient delivery to the muscle, providing more substrates for MPS. 518	
However, it has been shown on several occasions that enhanced muscle blood flow 519	
does not augment anabolic responses in young or older males (164, 187–189). 520	
Nonetheless, dietary arginine (the principle substrate for endothelial nitric oxide 521	
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synthase (eNOS) for endogenous production of NO) supplementation did increase 522	
the weight of the soleus and EDL muscle in obese rats (125). However, in humans 523	
Tang and colleagues found oral arginine (10g), of which approximately 70% is 524	
bioavailable following ingestion (154), had no effect on muscle blood flow or MPS 525	
when provided alone or in combination with AA or acute RE (232). In contrast, 526	
vasodilatory effects of arginine have been shown when administered by IV infusion 527	
at higher doses (30g) (23). By comparison, the peak in plasma arginine was 528	
considerably lower following 10 g of oral arginine (~225 µmol.L-1) (232) versus 30g 529	
IV infused arginine (~6223 µmol.L-1) (23), thus the dose of arginine used by Tang 530	
and colleagues may not have been sufficient to increase plasma arginine to an 531	
amount which elicits effects on vasodilation. In fact the authors project that on the 532	
premise of 70% bioavailability, a total of ~43 g of oral arginine would have been 533	
required to reach similar plasma levels reported following IV infusion (232). An 534	
alternative may be to utilize the arginine precursor citrulline (156), which bypasses 535	
splanchnic extraction (267). Supplementation of citrulline in rodents was shown to 536	
stimulate MPS (179) via the mTORC1 pathway (193). However, similar effects 537	
have not been observed in humans, since there was no additional impact of citrulline 538	
(10g), when co-ingested with whey, on MPS or blood flow with or without acute RE 539	
versus whey combined with non-essential AA (NEAA) (52). Lastly, flavanols such 540	
as in cocoa (39, 109) also promote vasodilation via NO pathways (80, 132). It was 541	
recently reported that despite an acute dose of cocoa flavanols (350mg) increasing 542	
macro- and microvascular blood flow, this was not associated with enhanced muscle 543	
anabolic responses to nutrition (188), suggesting in healthy individuals nutrient 544	
delivery is not rate-limiting for muscle anabolism (189). 545	
 546	
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In contrast to muscle mass and strength related studies, a plethora of research has 547	
investigated the effects of nitrates and EE on whole body metabolism and endurance 548	
performance. An early study by Larsen et al. (2007) reported that sodium nitrate 549	
supplementation reduced the O2 cost of submaximal cycling exercise (148), whilst 550	
similar results have reported following nitrate-rich beetroot juice supplementation 551	
(11), indicative of improved aerobic metabolism or mechanical efficiency (147). In 552	
addition to metabolic improvements, nitrate supplementation provided in the form of 553	
500ml beetroot juice improved 4 and 16.1km cycling time trial performance in 554	
trained cyclists (145). These improvements are likely attributable to an enhanced 555	
rate of PCr recovery (239) increasing the rate of ATP synthesis, although this 556	
mechanism remains speculative at present. Emerging evidence from cell culture 557	
studies suggests nitrate supplementation enhances mitochondrial biogenesis and 558	
oxidative metabolism via increased 5’adenosine monophosphate-activated protein 559	
kinase (AMPK) and peroxisome proliferator-activated receptor γ co-activator 1α 560	
(PCC-1α) gene expression (240), though in vivo data is lacking. Although others 561	
have also reported nitrate-mediated improvements in EE performance have been 562	
shown (169, 269), several authors have shown no improvements (6, 48, 254). For 563	
example, consuming 140ml of beetroot juice 2.5h prior to a 1h cycling time trial did 564	
not improve time trial performance in trained cyclists compared to placebo (48). 565	
These discrepant findings may be explained by methodological differences such as 566	
the dose of nitrates (since the increase in plasma NO3- and NO2- is somewhat dose 567	
dependent (270)), control of nitrate intake, the source of nitrates provided and the 568	
training status of the participants. For example, since numerous studies demonstrate 569	
nitrate supplementation to have no beneficial effect on performance in well trained 570	
participants (6, 48, 254), it is likely that fitness status influences the ergogenic 571	
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potential of nitrate supplementation (127). Indeed, higher plasma levels of NO2- 572	
were present in trained versus untrained participants pre and post acute exercise 573	
(195). This may be explained by higher nitric oxide synthase (NOS) activity (159) 574	
and/ or higher plasma nitrate values (195) in trained participants.  575	
 576	
Thus, it is established that nitrates reduce the O2 cost of aerobic exercise. Further in 577	
vivo work is required to understand whether larger oral doses, than those already 578	
tested, of arginine can enhance vasodilation and effects protein metabolism, across 579	
different ages. Furthermore, precise mechanisms regulating the nitrate-induced 580	
beneficial effect on O2 cost remain to be delineated in vivo.  581	
 582	
β-alanine and carnosine 583	
β-alanine (BA) is a beta AA produced endogenously in the liver found primarily in 584	
meat (238). BA is the rate-limiting precursor for the synthesis of carnosine, which is 585	
a dipeptide of BA and histidine that improves the muscle buffering capacity (222). 586	
BA supplementation has generated interest as an ergogenic aid since early studies 587	
found BA supplementation capable of increasing muscle carnosine stores by ~40-588	
65% demonstrating good bioavailability; a consistent and reproducible finding (16, 589	
108, 222). Although the extent to which carnosine content increases may be 590	
dependent on the dosing protocol (108). Other factors have been shown to cause 591	
muscle carnosine variability, including gender, age, dietary BA intake, 592	
vegetarianism (76) and fibre type distribution, since carnosine content is double in 593	
type II compared to type I fibres (38). The regulation of muscle carnosine stores 594	
from dietary/ supplemental sources is still under investigation (222). Oral BA may 595	
be transported across the gut via the H+-coupled PAT1 AA transporter (235), which 596	
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increases plasma availability of BA for muscle carnosine synthesis. Transport of BA 597	
into skeletal muscle has been shown to be regulated via both peptide transporter 2 598	
(PEPT2) (67) and the taurine transporter (TauT) (237), although this remains to be 599	
confirmed in humans. Once within the muscle cell, BA and sarcoplasmic histidine 600	
synthesize carnosine via carnosine synthase (222).  601	
 602	
Increased muscle carnosine stores may increase RE work capacity via regulation of 603	
the muscle buffering capacity during RE, and therefore has gained interest into the 604	
potential of BA supplementation for  promoting RE/T adaptations (133). However, 605	
10 weeks RET combined with 6.4g/day BA did not enhance body mass or strength 606	
changes in twenty-six males, despite increased muscle carnosine (133).  607	
 608	
During high intensity exercise, the build up of H+ ions reduces the intramuscular pH 609	
leading to fatigue likely due to acidosis-induced reductions in ATP generation (205). 610	
Increased muscle carnosine, via BA supplementation, is capable of reducing 611	
intramuscular acidity during high intensity exercise therefore enhancing exercise 612	
performance (57, 112, 229). For example, 4 and 10 weeks of BA supplementation 613	
increased cycling capacity (total work done) in untrained males when cycling at 614	
110% of maximum power (112), hypothesized to be due to improved intracellular 615	
buffering. In sprint-trained athletes, 4-5 weeks BA supplementation (4.8 g/day) led 616	
to increased knee torque but did not enhance sprint performance (64). Importantly, 617	
this study found increased muscle carnosine stores (+47%), demonstrating that it is 618	
possible to increase muscle carnosine even in trained athletes (64). Women 619	
supplemented with BA for 28 days delayed the onset of neuromuscular fatigue 620	
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(denoted by improved ventilatory threshold, physical working capacity and time to 621	
exhaustion), likely the result of improved intracellular buffering capacity (228).  622	
 623	
BA supplementation is associated with paresthesia (i.e. flushing) following acute 624	
doses of ≥800 mg (60, 108). This side effect is deemed dose-dependent and likely 625	
relating to BA plasma kinetics (108). Compared to pure BA, slow releasing BA 626	
capsules eliminated all paresthesia side effects, most likely explained by the 627	
attenuated BA plasma concentration and delayed time to peak (60), and thus offer a 628	
suitable alternative supplement option.  629	
 630	
BA supplementation may therefore be implemented to increase muscle carnosine 631	
stores which, in turn enhances acute EE performance, likely mediated via an 632	
enhanced intracellular buffering capacity. However, the effects of BA combined with 633	
RET needs to be studied further in vivo.  634	
 635	
Micronutrients: vitamins and exercise 636	
Vitamins are essential for many metabolic processes, however consuming vastly more 637	
or less than recommended can likely result in toxicity or deficiency, respectively  638	
(212), which can be detrimental for muscle health. For example, vitamin D (VitD) 639	
deficiency has been linked to muscle wasting (86) and as such, vitamins have been 640	
implicated in regulating muscle mass, metabolism and performance as discussed 641	
below.       642	
 643	
Vitamin D 644	
 645	
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VitD is a steroid hormone, the deficiency of which in humans throughout the world is 646	
reaching epidemic levels mostly due to reduced sun exposure (116). VitD deficiency 647	
is prevalent in many debilitating conditions including osteoporosis and rickets (116, 648	
117) and is associated with reduced muscle mass and strength (244). For example, 649	
rodent models have demonstrated VitD deficiency induced muscle loss, a 650	
consequence of increased MPB and reduced MPS compared to controls (17). The 651	
VitD receptor (VDR) is present in many tissues including muscle (89) which has led 652	
to increasing interest in the effects of VitD on muscle metabolism. Although 653	
conflicting reports exist regarding the presence of the VDR (192, 251), these 654	
discrepancies are most likely due to the use of non-validated antibodies, lack of 655	
controls or differences in antibody specificity (89).  656	
 657	
Following sun exposure or consumption of VitD-rich dietary sources/ supplements, 658	
circulating VitD bound to VitD binding protein (DBP) increases, and transports to the 659	
liver where hydroxylation (via 25-hydroxylase) generates 25-hydroxyvitamin D 660	
(25D). A second hydroxylation in the kidney (via 1α-hydroxylase) produces the 661	
biologically active form of VitD (1,25(OH)2D) (87). Mechanisms underpinning the 662	
effects of VitD on muscle metabolism are not fully understood but are believed to be 663	
in part related to the regulation of gene expression via the VDR or secondary 664	
messenger protein signaling (194). The binding of 1,25(OH)2D to the VDR causes 665	
conformational changes, allowing VDR to heterodimerize with the retinoid X receptor 666	
(RXR). This complex then binds to VitD response elements (VDREs) on the DNA, 667	
promoting gene transcription (45, 87). 1,25(OH)2D may also have non-genomic 668	
effects on intramuscular signaling by binding to a cell surface receptor (40), which, in 669	
turn, this activates intracellular signaling pathways such as the Akt and mitogen-670	
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activated protein kinases (MAPK) pathway (33). For example, VitD treatment 671	
increased myotube size, down-regulated myostatin (88), up-regulated Akt (33) and 672	
sensitized the Akt/ mTORC1 pathway and MPS responses to leucine and insulin 673	
(206) in muscle cell cultures. Thus, there is growing in vitro evidence for an anabolic 674	
role of VitD in skeletal muscle. In humans, supplementation of VitD has been 675	
proposed to increase muscle strength (13), function (83, 252), fibre area (46, 208, 676	
221), lean body mass (72) and reduce falls (83, 130), although a recent meta-analysis 677	
found no overall effects of VitD supplementation on muscle mass (13). Of 678	
importance, benefits of VitD supplements are observed particularly in the elderly or in 679	
those who are VitD deficient (13), which may be a potential explanation for some of 680	
the discrepant findings within the literature.  681	
 682	
Since VitD supplementation has been suggested to promote muscle mass and 683	
function, concurrent VitD supplementation with RET may be expected to potentiate 684	
exercise-induced adaptations. Indeed, 4 months VitD3 supplementation (1920IU/day 685	
plus 800mg/day calcium) in combination with lower-body RET for 3 months led to a 686	
greater reduction in myostatin mRNA expression, a negative regulator of muscle 687	
mass, and a greater change in the percentage of type IIa muscle fibres in young males 688	
(3). However, these changes did not translate into greater muscle strength or 689	
hypertrophy above RET alone (3). Elderly adults undertaking RET combined with 690	
VitD improved muscle quality (strength/ cross sectional area) more so than young 691	
males, thus demonstrating that elderly individuals may benefit more from VitD 692	
supplementation (3). VitD insufficient (according to VitD ranges by (118)) 693	
overweight and obese adults did not augment gains in lean body mass compared to 694	
placebo following 3 months RET and 4000IU/day VitD3 (41). This may be due to the 695	
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fact that VitD is deposited in body fat, reducing bioavailability (266) and requiring 696	
greater levels of VitD supplementation to promote muscle anabolism in this 697	
population. Similarly, others reported no change in body composition after 9 months 698	
supplementation of 400IU/day and RET 2x/week in overweight males and females 699	
(34). Since no change in body composition was seen in the training only group either, 700	
these findings may resulted from low training adherence (~53%) (34).  701	
 702	
Therefore, while there is some evidence to suggest an emerging role for the 703	
supplementation of VitD for the promotion of muscle mass and protein metabolism, 704	
more high-quality in vivo work is required. For example, investigations into the direct 705	
effect of VitD on MPS in humans are needed, as are more acute and chronic EE 706	
studies in order to understand the potential synergistic effects of VitD 707	
supplementation and exercise on muscle health. These studies need to be well 708	
controlled, accounting for basal VitD status and should determine true VitD 709	
bioavailability.  710	
 711	
Vitamins C and E (i.e. “antioxidants”)  712	
High levels of free radicals (an atom with a single unpaired electron) and reactive 713	
oxygen species (ROS) can disrupt protein homeostasis (196). This is likely due to 714	
ROS promoting catabolism via increases in the ubiquitin-conjugating activity (150) 715	
and diminishing anabolism via attenuation of MPS and signaling proteins (182), with 716	
evidence for these mechanisms arising from cell culture studies. It is therefore thought 717	
that consuming dietary antioxidants (i.e. vitamin C (VitC) and E (VitE)) capable of 718	
donating an electron to neutralize free radicals (168), may reduce ROS thus 719	
minimizing disruption of protein homeostasis. For instance, a positive relationship 720	
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was observed between VitC intake and appendicular lean body mass (209), which 721	
may be related to the fact that muscle is a major storage site for VitC (253). 722	
 723	
However, physiological levels of ROS such as that produced during exercise (248) 724	
promote gene expression (e.g. manganese superoxide dismutase (MnSOD)) (185) and 725	
cell signaling (e.g. c-Jun N-terminal kinases and MAPK’s) (92, 185) in healthy 726	
skeletal muscle. Thus, it may be hypothesized that provision of antioxidants combined 727	
with RET could hamper exercise-induced adaptations. Human studies assessing the 728	
interactions of RET and antioxidant supplementation have produced varied results 729	
with support for positive (22, 143), negative (19, 184) and negligible (21, 184) effects 730	
of antioxidants. For example, greater gains in fat free mass were observed following 6 731	
months RET combined with VitC (1000mg/day) and VitE (600mg/day) compared to 732	
RET alone, postulated to be a result of antioxidants increasing protein synthesis, 733	
although this was not measured (22, 143). However, 3 months supplementation of 734	
daily VitC (1000mg) and VitE (235mg) alongside whole body RET led to blunted 735	
gains in total lean body mass and muscle thickness (19). Ten weeks whole body RET 736	
combined with 1000mg VitC and 235mg VitE daily found negligible effects on acute 737	
MPS and muscle mass, however, the phosphorylation of anabolic signaling proteins 738	
was blunted compared to placebo (184). Supporting the lack of ability to potentiate 739	
exercise-induced adaptations, RET and antioxidants increased fat free mass but no 740	
more than RET alone (21). This may be a result of the low participant numbers or due 741	
to the fact that the participants were not vitamin deficient, therefore it may be that 742	
additional vitamin intake provides little or no added benefits. The absorption of 743	
antioxidants, particularly VitC, may also be limited, (21) further reducing the 744	
antioxidant-induced anabolic potential. Another factor which may explain the efficacy 745	
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of antioxidant supplements is the age of participants since the elderly have an altered 746	
redox status (184), which could impact the efficacy of the antioxidants. 747	
 748	
Detrimental and negligible interactions have also been reported following EE and 749	
antioxidant supplementation (183, 272). For example, daily VitC (1000mg) and VitE 750	
(235mg) during an 11 week EE training program consisting of steady-state and HIIT 751	
in humans led to blunted increases in mitochondrial protein content, indicative of 752	
blunted mitochondrial biogenesis, although no differences were observed in VO2Max 753	
compared to placebo (183). Similarly, VitC hampered running time to exhaustion in 754	
rats, perhaps a result of impaired mitochondrial biogenesis (93). Others have reported 755	
no alterations in EE-induced adaptations (measured as maximal O2 consumption, 756	
power output and workload at lactate threshold) following antioxidant 757	
supplementation (272). Differences in the antioxidant dosing regimes might explain 758	
some divergent findings between studies (183). Thus, whilst VitC and VitE are vital 759	
for maintaining health, the benefits of supplementation are debatable and are likely to 760	
depend on the age group deficiency status. The poor bioavailability described in 761	
several studies may further impact any benefits of supplementation (21).  762	
 763	
Currently, it is difficult to conclude whether antioxidant supplementation is beneficial 764	
or detrimental for muscle mass, protein metabolism and performance/adaptation. 765	
Close and colleagues highlighted that confusion and misguided conclusions are often 766	
drawn due to inappropriate methodological techniques (53). As an example, the lipid 767	
peroxidation marker, thiobarbituric acid reactive substances (TBARS), can be the 768	
result of non-redox related sources and is thus no longer recommended for use as an 769	
oxidative stress marker (81), yet is often published in the context of antioxidant 770	
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supplementation (111, 155, 157). It is believed that diets rich in fruits and vegetables 771	
as opposed to large supplemental doses of antioxidants are preferable since no 772	
investigations to date support attenuations in adaptations to training in response to 773	
fruits and vegetables, which have naturally occurring antioxidants (53).  774	
 775	
Emerging Nutraceuticals  776	
Ursolic acid 777	
Despite the paucity of research at present, other novel nutraceuticals have gained 778	
recent attention for their potential to promote muscle mass, protein metabolism and/or 779	
exercise adaptations. For example, the naturally occurring phytochemical ursolic acid 780	
(UA) found in apple peel has drawn attention since UA supplemented mice gained 781	
7% muscle weight (142), suggesting UA may be capable of promoting muscle 782	
hypertrophy (71, 124, 141, 142). UA-induced hypertrophic effects are proposed to be 783	
due to the attenuation of atrophy-related genes MuRF1 and atrogin-1, and the up-784	
regulation in IGF gene expression (142). Contrary to this, UA incubations in cell 785	
cultures was reported to inhibit leucine-stimulated mTORC1 signaling by inhibiting 786	
mTORC1 localization to the lysosome (180), a key step in AA-induced anabolic 787	
signaling (207). Research is warranted to detail the effects of UA on muscle 788	
metabolism in humans.  789	
 790	
With regards to exercise interactions, UA injection following RE in rats stimulated 791	
p70S6K1 at 1h and was maintained 6h later, which began the descent to baseline in 792	
the exercise only group, reflecting prolonged mTORC1 activity and thus anabolic 793	
potential when RE is combined with UA (177). Despite an unclear mechanism, the 794	
authors speculated that IGF-I may contribute to the UA-induced p70S6K1 activation, 795	
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and previous work supports this hypothesis (142). Contrary, data in humans (not in 796	
the context of UA) shows no change in IGF-I but increased anabolic signaling after 797	
acute RE (28). In RE trained males, RET 6 x/week (at 60-80% of 1-RM) for 2 months 798	
combined with 450mg/day UA improved leg strength but had no effect on lean body 799	
mass, although RET alone also had no effects on lean body mass (12). This may be 800	
due the fact that the participants had >3 years RET experience, and hypertrophic 801	
responses predominate in the early stages of RET (29). To the author’s knowledge, no 802	
evidence exists regarding UA supplementation combined with EE. An important issue 803	
to consider is the low and variable bioavailability of UA following oral ingestion, 804	
likely due to its lack of solubility in aqueous solutions (113). This could markedly 805	
impact its potential as a nutraceutical. However, recent efforts have been made to 806	
improve the bioavailability of UA and other triterpenoids by, for instance, using nano-807	
liposomes to aid solubility (271). The varied and low bioavailability of UA in humans 808	
is demonstrated by the lack of UA content in some participants following a 1g oral 809	
dose, and in those that did display UA content, it was only observed up to 12h post 810	
consumption (113). Additional findings show oral UA ingestion (3g) lead to increased 811	
plasma UA 2 and 6h post-exercise (50). As such, the true bioavailability of UA in 812	
response to time and dose should be investigated further.  813	
 814	
Phosphatidic acid 815	
Phosphatidic acid (PA) is a diacyl-glycerophospholipid found endogenously in 816	
mammalian cell membranes that can be obtained exogenously from raw cabbage 817	
(231). Both endogenous and exogenous PA are believed to positively influence 818	
muscle protein metabolism, whereby endogenous PA can be increased by RE and 819	
directly binds to mTORC1 influencing MPS. Exogenous PA indirectly stimulates 820	
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mTORC1 activation (77, 165) via extracellular-signal regulated protein kinase 821	
(ERK) dependent (262), and phosphatidylinositol-3-kinase (PI3K) independent 822	
(176) mechanisms, and may also attenuate MPB via attenuation of atrophy-related 823	
genes (210). Exogenous PA in cultured muscle cells also prevented atrophy in the 824	
presence of the atrophy-inducing substances tumor necrosis factor alpha (TNF-α) 825	
and dexamethasone (122). Recently, acute PA supplementation in rodents tended to 826	
increase MPS in the fasted state, however, PA blunted the whey protein induced rise 827	
in MPS (165). Possibly the addition of PA to whey alters the pathways of mTORC1 828	
activation thus shifting peak MPS (165); research is needed to understand the 829	
signaling responses of PA alone versus PA plus whey. In a human case study, orally 830	
ingested PA metabolized into lysophosphatidic acid (LPA) and glycerophosphate, 831	
increased plasma PA and LPA 30 minutes post-ingestion (of 1.5g PA), which 832	
plateaued at 1-3h and remained elevated above baseline at 7h (197). Thus, it seems 833	
PA is bioavailable in humans, although beyond 7h post-ingestion the bioavailability 834	
is unknown and further studies with a larger cohort are needed to determine the true 835	
bioavailability of PA. PA supplementation (750mg daily) combined with 2 months 836	
supervised whole body RET in RE trained males found increased lean body mass 837	
and cross sectional area compared to the placebo group (129). Conversely, others 838	
have shown non-significant increases (+2.6%) in lean body mass, despite utilizing a 839	
similar RET and supplementation programme (115). The differential findings 840	
between these studies may be due to the fact that training was unsupervised in the 841	
later study. To our knowledge no data currently exists assessing the interactions of 842	
PA plus EE.  843	
 844	
Combined nutraceuticals  845	
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Although not the focus of this review, it is worth speculating that combining 846	
nutraceuticals may provide multiple benefits to skeletal muscle health or potentiate 847	
skeletal muscle health benefits in response to exercise. Consequently, some studies 848	
have investigated the potential of combined nutritional ‘cocktails’. For example, a 849	
supplement containing PA, HMB and VitD in combination with 2 months RET led 850	
to greater gains in lean body mass and strength compared to the placebo group, 851	
providing support that the combined supplement possessed anabolic properties (73). 852	
The combination of VitD, leucine and whey twice daily in tandem with RET 3 853	
x/week for 13 weeks prevented the loss of appendicular muscle mass during 854	
intentional weight loss in obese males and females (243). The caveat with 855	
implementing combined nutritional supplementation is that it is difficult to attribute 856	
changes in the endpoint to the responsible individual/ or combination of nutrients, 857	
unless rigorous study designs are implement with adequate control groups.  858	
 859	
Conclusion and Future Directions 860	
While it is extremely unlikely that a single nutraceutical will prove to be a ‘magic 861	
bullet’, it is clear that certain nutraceuticals, under certain conditions, do indeed 862	
possess ergogenic potential. Of the nutrients discussed herein, strong evidence exists 863	
for leucine, HMB and Cr for muscle mass; leucine and HMB for protein metabolism; 864	
carnitine for fuel metabolism and leucine, HMB, carnitine, Cr, nitrates and β-alanine 865	
for athletic (strength or endurance) performance. Further empirical in vivo evidence is 866	
required to firmly establish the currently emerging roles of VitD, UA and PA for 867	
promoting muscle mass and n-3 PUFA, UA and PA for muscle protein metabolism. 868	
This review highlights: 1) the need for better controlled longer duration human 869	
studies which investigate the role of individual nutrients on muscle mass, protein/ fuel 870	
	 36	
metabolism and indices of exercise performance/ adaptation, 2) the lack of in vivo 871	
“mechanistic” studies, and 3) the need to determine the bioavailability of emerging 872	
nutrients.   873	
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Figure 1. Proposed metabolism and mechanisms of action for nutrients/ nutraceuticals.  1816	
→ represents activation;  represents purported activation; --| represents purported suppression; ? unknown; 4EBP1 4E binding protein-1; AA 1817	
amino acids; AMPK 5' AMP-activated protein kinase; AO antioxidants; ATP adenosine triphosphate; CARNS carnosine synthase; CHO 1818	
carbohydrate; CK creatine kinase; EDG-2 endothelial differentiation gene; eEF2 eukaryotic elongation factor 2; eIF4E eukaryotic initiation 1819	
factor 4E; HMB β-hydroxy-β-methylbutyrate; MPS muscle protein synthesis; mTORC1 mammalian target of rapamycin complex 1; NO3-; 1820	
nitrate; NO2- nitrite; NO nitric oxide; OCTN2 organic cation transporter 2; PA phosphatidic acid; PAT1 proton-coupled amino acid transporter 1; 1821	
PEPT2 peptide transporter 2; PGC-1α peroxisome proliferator-activated receptor-γ coactivator-1α; RPS6 ribosomal protein S6; SLC6AS Solute 1822	
Carrier Family 6 Member 8; TauT taurine transporter; UA ursolic acid; VDR vitamin D receptor; VDRE vitamin D response elements; VitD; 1823	
vitamin D; VitD3; active vitamin D.  1824	
 1825	
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Table 1. Summary of studies in humans demonstrating positive, negative or negligible effects of established and emerging macronutrients, 1828	
micronutrients and nutraceuticals on skeletal muscle mass, metabolism and performance with or without exercise 1829	
(INSERT TABLE HERE) 1830	
 1831	
↓ decrease, ↑ increase,  > larger,  ←→ no change, 1-RM: one repetition maximum; AA: amino acids; Arg: arginine; AS: antioxidant supplement; 1832	
β-ala: beta-alanaine; BRJ: beetroot juice; BW: body weight; CAR: carnitine; CHO: carbohydrate; CON: control; CONC: concentric; CPK: 1833	
creatine phosphokinase; CR: creatine; CSA: cross-sectional area; d: day/s; EAA: essential amino acids; ECC: eccentric; EE: energy expenditure; 1834	
EET: endurance exercise training; F: females; FFM: fat free mass; FO: fat oxidation; FSR: fractional synthesis rate; g: grams; h: hours; HIIT: 1835	
high intensity interval training; HMB: β-hydroxy-β-methylbutyrate; kg: kilograms; km: kilometer; LBF: leg blood flow; LBM: lean body mass; 1836	
LCA-CoA: long-chain acyl-CoA; LDH: lactate dehydrogenase; LEU: leucine; n-3 PUFAs: n-3 polyunsaturated fatty acids; NEAA: non-essential 1837	
amino acids; M: males; Max: maximal; MBV: microvascular blood volume; Mg: milligrams; Min: minute; ml: milliliter; mmol: milimolar; 1838	
MPO: mean power output; MPB: muscle protein breakdown; MPS: muscle protein synthesis ; mRNA: messenger ribonucleic acid; mTOR: 1839	
mammalian target of rapamycin; NaNO3: sodium nitrate; NS.: non-significant; O: old; O2: oxygen; OBLA: onset of blood lactate accumulation; 1840	
p70S6K1: ribosomal s6 kinase 1; PDH: pyruvate dehydrogenase; PLA: placebo; Pmax: maximal power output; PPO: peak power output; PRO: 1841	
protein; PWCFT: Physical working capacity at the onset of neuromuscular fatigue threshold; Reps: repititions ; RE: resistance exercise ; RET: 1842	
resistance exercise training; TART: tartrates; TC: total carnitine; TT: time trial; TTE: time to exaution; TUG: timed up and go; TWD: total work 1843	
done; VitD: vitamin D; VT: ventilatory thresehold; Wk/s: week/s; Y: young; yr: year; Yo-Yo IR1: Yo-Yo intermittent recovery level 1 1844	
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n=8: 3.42g 
HMB (2.42g 
pure HMB) 
n=7: 3.42 g 
LEU 
 
 
− 
 
HMB & LEU ↑ MPS, 
HMB ↑ mTOR 
signalling > LEU, 
HMB ↓ MPB 
HMB 
promotes ↑ 
MPS and ↓ 
MPB 
Metabolism 
Deutz 2013 
 
Nutraceutical 4 M  
15 F 
 
n=11: 3g/d 
HMB 
n=8: PLA 
 
10d bed rest HMB ←→ LBM 
PLA ↓ LBM 
 
HMB 
preserves 
muscle mass 
during disuse 
 
Mass 
Baier 2009 Nutraceutical 38 M 
39 F 
n=40: 2 or 3g 
HMB, 1.5 or 
2.25g lysine, 
5 or 7.5 g 
arginine & 
0.1g ascorbic 
acid 
n=37: PLA 
1yr 
- ↑ FFM AA cocktail 
enhanced 
muscle mass 
Mass 
Panton 2000 Nutraceutical 39 M  
36 F 
n=36: HMB 
(3g/d) 
n=39: PLA 
RET 3*wk  
4 wks 
↑ strength > PLA HMB 
improved 
muscle 
function 
Performance 
Wilson 2014 Nutraceutical 20 M n=11: HMB 
(3g/d) 
n=9: PLA 
Periodised RET  
12 wks 
↑ strength, power and 
LBM vs. PLA 
HMB 
enhances 
muscle 
function & 
hypertrophy 
Mass 
Performance 
Vukovich 2001 Nutraceutical 8 M 
 
n=8: 3g/d 
HMB  
n=8: 3g/d 
LEU 
n=8: 3g/d 
PLA 
2wks 
 
- HMB ↑ time to reach 
VO2peak  
HMB & LEU ↑ 
OBLA 
HMB 
improves 
aerobic 
performance 
Performance 
Miramonti 
2016 
Nutraceutical 22 M  
15 F 
n=14: 3g/d 
HMB 
n=14: 3g/d 
PLA 
n=9: CON 
4 wks 
 
HIIT 3*wk 
4 wks 
↑ PWCFT following 
HMB > PLA & CON 
HMB & HIIT 
improves 
aerobic 
performance 
Performance 
Knitter 2000 Nutraceutical 5 M 
8 F 
n=8: 3g/d 
HMB 
n=5: PLA 
6 wks 
 
Running >30 
km/wk 
Attenuated ↑ in CPK 
& LDH post 20 km 
run following HMB 
HMB 
ameliorates 
aspects of 
muscle 
damage 
Performance 
Creatine 
Greenhaff 1993 
 
Nutraceutical 9 M 
3 F 
 
n=6: 20g/d 
CR + 1g/d 
glucose/ 
n=6: 24g/d 
glucose 
5d 
5 x 30 max 
voluntary 
contractions, before 
and after 
supplementation 
CR ↓ peak 
torque decline 
 
CR sustains 
performance 
 
Performance 
Birch 1994 Nutraceutical 14 M n=7: CR 
20g/d 
n=7: PLA 
5d 
3 x 30 sec max 
cycling sprints 
CR ↑ PPO, MPO and 
total work output 
during 1st sprint 
CR increases 
aspects of 
power output 
Performance 
 
Earnest 1995 Nutraceutical 8 M n=4: 5g/d CR 
n=4: PLA 
2-4 wks 
3 x 30 sec max 
cycling  
1-RM test 
70% of 1-RM until 
fatigue 
 
CR ↑ total anaerobic 
work during cycling 
sprints, ↑ BW, ↑ total 
lifting volume 
 
CR enhances 
muscle 
function  
Mass & 
Performance 
 
Cooke 1995 Nutraceutical 12 M n=6: 5g CR + 
1g glucose 
n=6: PLA 
5d 
 
Max cycling sprint ←→ in power 
indices 
CR does not 
affect power 
output 
Performance 
 
Mujika 1996 Nutraceutical 11 M 
9 F 
n=10: 20g/d 
CR 
n=10: PLA 
1 wk 
 
20, 50 & 100 m 
max swim 
No difference in race 
time between groups 
CR has no 
ergogenic 
benefits on 
sprint 
performance 
Performance 
 
Snow 1998 Nutraceutical 8 M n=4: 30g/d 
CR + 30g/d 
dextrose 
n=4: PLA  
5d 
20 sec max cycling  CR did not affect 
power indices 
CR has  no 
ergogenic 
benefits on 
sprint 
performance   
Performance 
Thompson 1996 Nutraceutical 10 F n=5: 2g/d CR 
n=5: PLA 
6 wks 
 
6 wks swimming 
(part of a swim 
team)  
←→ in lean mass, 
resynthesis of PCr or 
performance time 
CR has no 
effect on body 
composition, 
anaerobic or 
aerobic 
performance 
Mass & 
Performance 
Cooke 2009 Nutraceutical 14 M n=7: 0.1-
0.3g/kg/d CR 
+ CHO 
n=7: CHO 
19d 
4 sets, 10 ECC reps 
@ 120% of CONC 
1-RM for 3 leg 
exercises  
CR+CHO ↑ 
isokinetic & 
isometric strength 
during recovery vs. 
CHO  
CR improves 
functional 
recovery 
Performance 
Volek 1999 
 
Nutraceutical 19 M n=10: 25 g/d 
1 wk, 5 g/d 11 
wks CR 
n=9: PLA 
 
RET 12 wks 
 
> ↑ in strength, CSA, 
following CR vs. 
PLA 
CR potentiates 
RET-induced 
muscle 
adaptations  
Mass & 
Performance 
Brose 2003 Nutraceutical 15 M  
13 F 
 
n=14: 5g/d  
CR + 2g 
dextrose 
n=14: pla 
RET 3*wk, 14 wks > ↑ in FFM and  
strength  following  
CR vs. PLA 
CR potentiates 
RET-induced 
mass and 
functional 
adaptations 
Mass & 
Performance 
Carnitine 
Stephens 2006 Nutraceutical 7 M n=7: 5h CAR 
infusion (15 
mg/kg prime, 
10 mg/kg.h 
constant) 
n=7: PLA 
- CAR ↑ muscle 
glycogen, LCA-CoA 
& ↓ PDH complex 
activity, lactate vs. 
PLA 
CAR can 
inhibit CHO 
oxidation 
Fuel 
Metabolism 
Wall 2011 Nutraceutical 14 M n=7: 2 g CAR 
+ 80 g CHO 
n=7: 80 g 
CHO 
2*d, 24 wks 
30 mins cycling @ 
50% VO2max, 30 
mins at 80% 
VO2max, 30 min all-
out 
@ 50% VO2max 
carnitine ↓ glycogen 
use 
 
CAR spares 
muscle 
glycogen 
Metabolism 
& 
Performance 
Stephens 2013 Nutraceutical 12 M n=6: 1.36 
CAR + 80g 
CHO 
n=6: 80g 
CHO 
2*d, 12 wks 
30 min cycling @ 
50% VO2max 
CAR ↑ LCA-CoA 
↑ fat mass in CHO 
CAR 
prevented fat 
mass gain 
Metabolism 
Abramowicz 
2005 
Nutraceutical 6 M 
6 F 
n=12: 1*3g 
CAR + TART 
n=12:  3g/d 
CAR + 
TART, 14d 
n=12: PLA, 
14d 
 
 
60 min cycling @ 
60% VO2max 
CAR + TART for 
14d ↑ CHO oxidation 
in M vs. PLA 
No effect on FO 
CAR & TART 
promote CHO 
oxidation 
during 
exercise 
Metabolism 
Broad 2005 Nutraceutical 15 M n=15: 3g/d 
CAR + TART 
n=15: PLA 
4 wks 
90 min cycling @ 
65% VO2max, 20 km 
TT 
FO and CHO similar 
between CAR & 
TART vs. PLA 
during exercise 
TT duration ↓ in PLA 
only  
 
CAR & TART 
enhance 
energy 
metabolism or  
endurance 
performance  
Energy 
Metabolism 
& 
Performance 
n-3 PUFAs 
Smith 2011 Nutraceutical 5 M 
4 F 
4g/d n-3 
PUFAs  
8 wks 
− 
 
↑ MPS 
& ↑ mTOR signalling 
during 
hyperinsulinaemia-
hyperaminoacidaemia 
n-3 PUFAs 
augments 
acute anabolic 
responses 
Metabolism 
Smith 2011 Nutraceutical 15 M 
29 F 
 
n=29: 4 g/d n-
3 PUFAs 
n=15: corn oil  
6 months 
− 
 
n-3 PUFAs ↑ mass & 
↑ strength vs. corn oil 
n-3 PUFAs 
promotes 
muscle growth 
Mass 
Huffman 2004 Nutraceutical 7 M n-3 PUFAs 4 
g/d  
3 wks 
 
60 mins running @ 
60% VO2max  
↑ fat EE Chronic  n-3 
PUFAs 
promote fat 
oxidation 
during 
exercise 
Metabolism 
Logan 2015 Nutraceutical 24 F n=12:  2g/d 
EPA + 1g/d 
DHA 
n=12: PLA 12 
wks 
Pre & post exercise 
testing 
n-3 PUFAs ↑ LBM, ↑ 
rate of FO & ↓ TUG 
n-3 PUFAs 
promotes fat 
metabolism, 
muscle mass 
and function 
Mass, Fat 
Metabolism 
and 
Performance 
Smith 2015 Nutraceutical 10 M 29 
F 
N=29: 
1.86g/d EPA 
+ 1.5 g/d 
DHA 
N=25: PLA 
24 wks 
- n-3 PUFAs ↑ muscle 
volume & strength 
vs. PLA 
n-3 PUFAs 
preserve 
muscle mass 
and function 
Mass & 
Performance 
Rodacki 2012 Nutraceutical 45 F n=15: 400 g/d 
EPA + 300g/d 
DHA 90d + 
RET 
n=15: 400 g/d 
EPA + 300g/d 
DHA 150d + 
RET 
N=15: RET  
RET 3*wk, 12 wks > ↑ in peak torque 
following n3-PUFAs 
vs. RET  
n3-PUFAs 
potentiate 
strength 
adaptations to 
RET 
Strength 
Performance 
McGlory 2016 Nutraceutical 19 M n=10: 5g/d 
n3-PUFAs 
n=9: PLA  
8 wks 
Acute RE 3 sets, 10 
reps @ 70% 1-RM 
Rest and exercise 
MPS similar 
following n3-PUFAs 
vs. PLA 
↑ p70S6K1 after RE 
in PLA only 
n3-PUFAs 
does not 
potentiate RE-
induced 
metabolic 
responses 
Metabolism 
Delarue 1996 Nutraceutical 4 M 
1 F 
n=5: 6g/d n-3 
PUFAs 
n=5: PLA  
3 wks 
- n-3 PUFAs ↑ FO & ↓ 
CHO oxidation 
n-3 PUFAs 
manipulates 
energy 
metabolism 
Energy 
Metabolism 
Delarue 2003 Nutraceutical 6 M n=6: 6g/d n-3 
PUFAs 
n=6: PLA  
20d 
Acute 90 min 
cycling @ 60% max 
O2 output 
n-3 PUFAs tended to 
↑ FO and ↓ CHO 
oxidation > PLA 
n-3 PUFAs 
might 
manipulate 
energy 
metabolism 
during 
exercise 
Energy 
metabolism 
Nitrates/Blood flow 
Tang 2011 Nutraceutical 8 M n=8: 10g 
EAA + 10g 
Arg 
n=8: PLA 
Unilateral acute RE, 
5 sets 8-10 reps 
↑ in blood flow 
and MPS 
following RE 
similar in Arg vs. 
PLA 
Arg has no 
additive 
effects on 
muscle blood 
flow or MPS 
Protein 
Metabolism 
Churchward-
Venne 2014 
Nutraceutical 21 M n=7: 45g 
Whey 
n=7: 10g 
citrulline + 
15g whey 
n=7: 10g 
NEAA + 15g 
whey 
 
Acute RE: 
6x8-10 reps @ 80% 
10-RM 
knee extension 
No ↑ in MPS, 
blood flow or 
perfusion 
following 
citrulline+whey 
vs. NEAA+whey 
No additive 
effect of 
citrulline on 
metabolism 
Protein 
Metabolism 
Phillips 2016 Nutraceutical 20 M n=10: 350 mg 
cocoa 
flavanol 
n=10: CON 
- ↑ LBF and MBV 
following cocoa 
flavanol 
←→ MPS 
following cocoa 
flavanol vs. CON 
Cocoa 
flavanols 
improve 
vascular but 
not MPS 
responses to 
nutrition 
Protein 
Metabolism 
Lansley 2011 Nutraceutical 9 M n=9: 500 ml 
BRJ 
n=9: 500 ml 
PLA 
4 & 16.1 km 
cycling TT 
↑ TT performance Nitrates 
improve TT 
performance 
Performance 
Larsen 2007 Nutraceutical 9 M n=9: 0.1mmol 
kg/d NaNO3 
n=9: PLA 
3d 
Sub-max and max 
cycling 
NaNO3 ↓VO2 at sub-
max vs. PLA 
NaNO3 
reduced O2 
cost during 
sub-max 
exercise 
Performance 
Bailey 2009 Nutraceutical 8 M n=8: 500ml/d 
BRJ 
n=8: PLA 
6d 
Moderate & intense 
exercise 
BRJ ↓VO2 during 
moderate exercise vs. 
PLA 
BRJ ↑ TTE during 
intense exercise 
BRJ can 
reduce  O2 
cost & 
improve 
exercise 
tolerance 
Performance 
Muggeridge 
2014 
Nutraceutical 9 M n=9: 1*70ml 
BRJ 
n=9: PLA 
15 min steady state, 
5 min rest, 16.1 km 
TT 
BRJ ↓VO2 during 
moderate exercise vs. 
PLA 
TT performance was 
faster following BRJ 
BRJ enhances 
endurance 
performance 
Performance 
Wylie 2013 Nutraceutical 14 M n=14: 490ml 
BRJ over 30h 
n=14: PLA 
Yo-Yo IR1 BRJ ↑ Yo-Yo IR1 
performance vs. PLA 
BRJ improved 
high intensity 
running 
performance 
Performance 
Arnold 2015 Nutraceutical 10 M n=10: 70 ml 
BRJ 
n=10: PLA 
Incremental 
treadmill running 
+ 10km TT 
BRJ did not change 
TTE during 
incremental exercise 
or time to completion 
in the TT vs. PLA 
BRJ does not 
enhance 
endurance 
running 
Performance 
Cermak 2012 Nutraceutical 
 
20 M n= 20: 1*140 
ml BRJ 
n=20: PLA 
1h cycling TT TT performance & 
power output similar 
between BRJ vs. 
PLA 
BRJ does not 
improve 
endurance 
performance 
Performance 
Wilkerson 2012 Nutraceutical 
 
8 M n=8: 1*500ml 
BRJ 
n=8: PLA 
50 mile cycling TT No difference 
between BRJ vs. 
PLA for completion 
time & power output 
Trend for BRJ ↓VO2 
BRJ did not 
improve TT 
performance 
Performance 
β-alanine and Carnosine 
 
Kendrick 2008 Nutraceutical 26 M n=13: 6.4g/d 
β-ala 
n=13: PLA 
4 wks 
RET 4*wk, 10 wks Similar ↑ in 
strength & body 
mass 
No additive 
effect of β-ala 
on strength, 
mass 
Mass & 
Performance 
Hill 2007 Nutraceutical 25 M n=13: 4-
6.4g/d β-ala 
n=12: PLA 
- 4 & 10 wks of β-
ala ↑ TWD 
during cycling 
β-ala 
improves 
exercise 
capacity 
Performance 
Derave 2007 Nutraceutical 15 M n=8: 4.8g/d β-
ala 
n=7: PLA  
4-5wks 
Track & field 
~5*wk 
β-ala ↑ knee 
torque during 
repetitive 
exercise bouts 
β-ala 
attenuates 
fatigue 
Performance 
Stout 2007 Nutraceutical 22 F n=11: 3.2-
6.4g/d β-ala 
n=11: PLA  
4 wks 
 
- β-ala ↑ PWCFT, 
VT & TTE 
β-ala delays 
the onset of 
neuromuscular 
fatigue 
Performance 
VitD 
Agergaard 
2015 
Micronutrient 17 M, Y 
17 M, O 
n=7 Y, 7 O: 
1920 IU/d 
VitD + 800 
mg/d calcium 
n=10 Y, 10 
O: 800 mg/d 
calcium 
16 wks 
RET 3*wk @ 65-
85% 1-RM, 12 wks 
Fibre type IIa 
%age > ↑ & 
myostatin 
mRNA > ↓ in Y 
VitD vs. Y pla 
No difference in 
the ↑ of CSA and 
strength in VitD 
vs. calcium 
But no 
additive effect 
on mass or 
strength 
Mass and 
Performance 
Carrilo 2013 Micronutrient 11 M 
12 F 
n=10: 4000 
IU/d VitD  
n=13: PLA 
RET 3*wk @ 70-
80% 1-RM, 3 
months 
←→ LBM 
following VitD 
or PLA 
↑ peak power 
following VitD 
VitD has no 
impact on 
mass but can 
improve 
muscle power 
Mass & 
Performance 
Bunout 2006 Micronutrient 10 M 
86 F 
n=24: 800 
mg/d calcium 
+ 400 IU/d 
VitD  
n=24: 800 
mg/d calcium  
n=24: 800 
mg/d calcium 
RET 2*wk, 9 
months 
> improvement 
in TUG in VitD 
+ RET vs. RET 
VitD enhances 
muscle 
function 
Performance 
+ 400 IU/d 
VitD + RET 
n=24: 800 
mg/d calcium 
& RET 
Ceglia 2013 Micronutrient 21 F 4000 IU/d 
VitD  
4 months 
− 
 
↑ type I/II CSA VitD increases 
muscle fibre 
size 
Mass 
VitC and VitE 
Bobeuf 2010 Micronutrient 23 M, 
25 F 
n=11: AS 
(1000 mg/d 
VitC & 600 
mg/d VitE) 
n=12: PLA 
n=13: RET 
n=12: 
AS+RET 
 
RET 3*wk @ 80% 
1-RM, 6 months 
> ↑ FFM in 
AS+RET vs. 
PLA, RET or 
AS. 
AS potentiates 
RET-induced 
gains in FFM 
Mass 
Bjørnsen 2015 Micronutrient 34 M n=17: AS 
(1000 mg/d 
VitC + VitE 
235 mg/d) 
n=17: PLA 
 
RET 3*wk, 3 
months 
> ↑ in total LBM 
and muscle 
thickness in PLA 
vs. AS 
AS blunt ↑ in 
total LBM 
Mass 
Paulsen 2014 Micronutrient 21 M 
11 F 
n=17:  AS 
(1000 mg/d 
VitC + 235 
mg/d VitE) 
n=15: PLA 
RET 4*wk, 10 wks > ↑ p38 MAPK, 
p70S6K, ↑ 
ERK1/2 in PLA 
vs. AS 
Similar changes 
in FSR, CSA & 
total LM 
AS altered 
protein 
signalling but 
not muscle 
hypertrophy 
Mass & 
Metabolism 
 
Labontè 2008 Micronutrient 27 M 34 
F 
600 mg VitE 
+ 1000 mg 
VitC  
6 months 
RET 3*wk, 6 
months 
> ↑ FFM 
compared to 
RET alone 
AS potentiate 
FFM gains 
Mass 
 
 
 
Bobeuf 2011 Micronutrient 27 M 
30 F 
n=11: AS 
(1000 mg/d 
VitC + 600 
mg/d VitE) 
n=12: PLA 
n=13: RET 
n=12: 
AS+RET 
 
RET 3*wk @ 80% 
1-RM, 6 months 
Similar ↑ in FFM 
and strength in 
AS+RET vs. 
RET 
AS do not 
maximize 
strength or 
mass gains 
Mass & 
Performance 
Paulsen 2014 Micronutrient 26 M 
28 F 
n=27: AS 
(1000 mg/d 
VitC + 600 
mg/d VitE) 
n=27: PLA 
EET 3-4*wk, 11 
wks 
Similar ↑ in 
VO2max 
←→ COX4 and 
PGC-1α 
AS hampered 
mitochondrial 
cellular 
adaptations 
Performance 
Yfanti 2010 Micronutrient 21 M n=11: AS 
(500 mg/d 
VitC + VitE 
400 IU/d)  
n=10: PLA 
16 wks 
EET 5*wk, 12 wks Similar ↑ in  
VO2max, Pmax, 
workload at LT, 
muscle glycogen, 
muscle enzyme 
activity 
AS have no 
effect on 
adaptation to 
EET 
Performance 
Gomez-
Cabrera 2008 
Micronutrient 14 M n=5: VitC 
1g/d + EET 
n=9: EET  
EET 3*wk 65-80% 
of  VO2max, 8 wks 
Similar ↑ in  
VO2max 
VitC  has no 
effect on 
adaptation to 
EET 
Performance 
Ursolic Acid 
Bang 2014 Nutraceutical 16 M n=9: 450 
mg/d UA 
n=7: PLA 
RET 6*wk @60-
80% 1-RM, 8 
weeks 
> ↑ strength vs. 
PLA 
←→ LBM in 
UA or PLA 
 
UA promotes 
gains in 
strength but 
not LBM 
Performance 
 
 
 
 
Phosphatidic Acid 
Joy 2014 Nutraceutical 28 M n=14: 750 
mg/d PA 
n=14: PLA 
RET 3*wk, 8 wks > ↑ LBM, 
CSA & 
strength vs. 
PLA 
PA potentiates 
RET-induced 
mass and 
strength gains 
Mass & 
Performance 
 
 
 
	 Hoffman 2012 Nutraceutical 16 M n=7: 750 mg 
PA 
n=9: PLA 
RET 4*wk @ 70% 
1-RM, 8 wks 
NS. ↑ LBM 
& strength 
PA did not 
potentiate 
RET-induced 
gains in mass 
or strength 
Mass & 
Performance 
 
 
 
